Recombinant Mouse CD9 antigen (Cd9)

What is CD9 antigen and what are its key structural characteristics?

CD9 is a tetraspanin protein characterized as a type IV transmembrane glycoprotein with four transmembrane domains. It functions primarily in cell-cell adhesion and may play a significant role in signal transduction through interactions with low molecular weight GTP binding proteins . Structurally, CD9 belongs to the tetraspanin family of proteins that are plasma membrane proteins with multiple proposed functions, including activation and sorting of other membrane proteins . The protein's structure facilitates its involvement in targeting proteins to multivesicular bodies (MVBs) and exosomes, making it a valuable marker in exosome research.

Which cell populations express CD9 antigen in mice?

CD9 expression demonstrates a distinct pattern across murine immune cell populations. It is constitutively expressed on:

• Early B cells

• Eosinophils

• Basophils

• Activated T cells

• Marginal zone (MZ) B cells

• B1 cells

• Plasma cells

• Platelets (as a major surface component)

Notably, CD9 is expressed on most non-T acute lymphoblastic leukemia cells and on some acute myeloid and chronic lymphoid leukemia cells . CD9 serves as a unique marker for marginal zone B cells, which constitutively express CD9 at both the protein and mRNA level, while follicular (FO) B cells are CD9-negative in their resting state .

How does CD9 expression change during B cell differentiation and activation?

While marginal zone B cells constitutively express CD9, follicular B cells only express CD9 after activation and during differentiation to plasma cells. RT-PCR analysis confirms that MZ B cells, but not FO B cells, express CD9 mRNA transcripts in freshly isolated cells . When follicular B cells are stimulated with lipopolysaccharide (LPS), they begin to express CD9 in the late stages of differentiation toward plasma cells . This expression pattern makes CD9 a valuable marker for tracking B cell differentiation pathways.

The expression timeline shows:

• Day 1: No CD9 induction in FO B cells

• Day 3: A minor population of FO B cells begins to express surface CD9

• Day 5: Approximately 20% of cells express CD9 in high-density cultures, while up to 60% express CD9 in low-density cultures

CD9 appears to be expressed before syndecan-1 (Synd1), another plasma cell marker, depending on culture conditions, and then remains at consistent levels in Synd1+ cells .

What are the validated detection methods for mouse CD9 in research applications?

Based on available literature, several validated methods exist for detecting CD9 in murine samples:

Flow Cytometry: CD9 (clone 2310.9) recombinant mouse monoclonal antibody has been validated for flow cytometric analysis of CD9 expression on cell surfaces . This approach allows researchers to quantify CD9 expression on specific cell populations when combined with other cell surface markers.

Immunofluorescence Microscopy: Anti-CD9 antibodies have been validated for immunofluorescence applications, enabling visualization of CD9 localization in tissue sections or cultured cells .

Western Blot: For protein-level detection and quantification, western blot analysis using validated anti-CD9 antibodies provides information about expression levels across different cell types or experimental conditions .

RT-PCR: For mRNA-level detection, RT-PCR has been successfully employed to detect CD9 transcripts in sorted cell populations, as demonstrated in studies comparing MZ and FO B cells .

When selecting a primary antibody, researchers should consider using recombinant monoclonal antibodies like clone 2310.9, which provides consistent specificity and reproducibility .

How should researchers design experiments to study CD9 induction in B cell subsets?

When designing experiments to study CD9 induction in B cell subsets, researchers should consider the following methodological approach:

• Cell Isolation and Sorting:

  • Use FACS sorting to isolate pure populations of marginal zone B cells and follicular B cells

  • Verify purity using established markers (e.g., CD21, CD23) before proceeding with CD9 studies

• Culture Conditions:

  • Cell density significantly impacts CD9 expression kinetics, with low-density cultures (1×10⁴/ml) showing better induction (approximately 60% CD9+ cells) compared to high-density cultures (approximately 20% CD9+ cells at day 5)

  • Include appropriate stimulants:

    • LPS for plasma cell differentiation (CD9 appears after 3 days)

    • LPS plus IL-4 for generating isotype-switched IgG1+Synd1+ cells that also express CD9

• Time Course Analysis:

  • Monitor CD9 expression at multiple time points (day 1, 3, 5, and 7)

  • Correlate CD9 protein expression with mRNA levels at each time point

• Co-expression Analysis:

  • Analyze CD9 expression in conjunction with other markers (Synd1, CD43, Ly6C) to track differentiation stages

• Controls:

  • Include known CD9+ cells (MZ B cells) as positive controls

  • Use CD9-deficient cells or isotype controls for negative control staining

What controls should be implemented when using anti-CD9 antibodies in experimental procedures?

When using anti-CD9 antibodies in experimental procedures, the following controls should be implemented to ensure validity and reproducibility:

Isotype Control: For the CD9 recombinant mouse monoclonal antibody (clone 2310.9), an appropriate isotype control is the Monoclonal Mouse IgG1 Kappa (IGG1/1331) . This control helps distinguish specific from non-specific binding and should match the primary antibody's isotype, species, and concentration.

Positive Controls: Include known CD9-expressing cells such as:

• Marginal zone B cells

• Plasma cells

• Platelets
  These serve as benchmarks for positive staining patterns.

Negative Controls: Include:

• Freshly isolated follicular B cells (CD9-negative)

• Germinal center B cells (CD9-negative)

• Omission of primary antibody

Experimental Validation Controls:

• Verify specificity using CD9-deficient mice when available

• Demonstrate concordance between protein detection and mRNA expression

Titration Controls:

• Perform antibody titration to determine optimal concentration for specific detection

• Document signal-to-noise ratio at different antibody concentrations

Implementing these controls ensures reliable and reproducible results when working with anti-CD9 antibodies across various experimental platforms.

How can researchers distinguish between constitutive and induced CD9 expression in B cell populations?

Distinguishing between constitutive and induced CD9 expression requires a multifaceted approach:

Temporal Analysis Protocol:

• Perform baseline flow cytometry on freshly isolated B cell subsets before any stimulation

• Conduct parallel RT-PCR analysis of CD9 mRNA expression in the same populations

• Track CD9 expression at defined intervals (6h, 24h, 72h, 120h) after stimulation

• Compare expression kinetics between naturally CD9+ populations (MZ B cells) and inducible populations (FO B cells)

Marginal zone B cells show constitutive CD9 expression at both protein and mRNA levels in freshly isolated cells, while follicular B cells are CD9-negative initially but can be induced to express CD9 after prolonged LPS stimulation . The appearance of CD9+ cells correlates with the detection of CD9 mRNA in the cultures, indicating de novo synthesis rather than acquisition from other sources .

Identification Markers:

• Constitutive expression: Present in freshly isolated cells without stimulation

• Induced expression: Appears only after specific stimulation and increases over time

• Acquired expression: Rapid appearance without corresponding mRNA increase

A comparative analysis of CD9 expression in different mouse strains (BALB/c and C57BL/6) confirms that the pattern of constitutive CD9 mRNA expression in MZ B cells is consistent across genetic backgrounds .

What methodological approaches can resolve contradictory findings in CD9 expression studies?

When researchers encounter contradictory findings in CD9 expression studies, the following methodological approaches can help resolve discrepancies:

Multi-level Analysis Protocol:

• Compare protein expression using multiple detection methods (flow cytometry, western blot, immunofluorescence)

• Correlate protein detection with mRNA expression using RT-PCR or RNA-seq

• Examine post-transcriptional regulation mechanisms that might explain protein-mRNA discrepancies

• Investigate culture condition effects on expression patterns

Research has shown that culture density significantly impacts CD9 induction, with low-density cultures (1×10⁴/ml) showing approximately 60% CD9+ cells by day 5, compared to only 20% in high-density cultures . This finding illustrates how methodological variables can produce seemingly contradictory results.

Standardization Approaches:

• Use consistent antibody clones across studies (e.g., clone 2310.9 for mouse CD9)

• Standardize flow cytometry gating strategies and presentation

• Report detailed experimental conditions, including cell densities and culture media composition

• Include positive and negative controls in each experiment

Genetic Confirmation:

• Use CD9-deficient mice as negative controls

• Perform gene knockdown/knockout studies to confirm antibody specificity

• Consider strain-specific differences in expression patterns

How do CD9 expression patterns in mice translate to human systems in translational research?

Translating findings from mouse CD9 studies to human systems requires careful consideration of similarities and differences:

Expression Pattern Comparison:
CD9 expression shows both similarities and differences between mouse and human immune cells:

• In both species, CD9 is expressed on early B cells, eosinophils, basophils, and platelets

• Human tonsil plasma cells express CD9, similar to murine plasma cells

• Both species use CD9 as an exosome marker protein

Methodological Approach for Cross-Species Translation:

• Perform parallel analyses of mouse and human samples using species-specific antibodies

• Compare expression patterns across equivalent cell populations defined by conserved markers

• Validate functional significance through comparable functional assays

• Use humanized mouse models when appropriate for verification

Verification Techniques:

• Confirm antibody specificity for the appropriate species-specific CD9 variant

• Utilize recombinant protein standards from both species for quantitative comparisons

• Perform side-by-side flow cytometry analysis of equivalent human and mouse cell populations

While mouse models provide valuable insights, researchers should recognize that expression patterns and functional significance may vary between species, necessitating direct validation in human systems for translational applications.

How should researchers analyze CD9 expression data in the context of B cell development?

When analyzing CD9 expression data in B cell development contexts, researchers should implement the following analytical framework:

Developmental Timeline Analysis:

• Establish a comprehensive B cell developmental map with defined stages

• Plot CD9 expression levels (MFI or percent positive) against developmental markers

• Identify transition points where CD9 expression changes significantly

• Correlate with functional capabilities at each stage

Based on available data, CD9 expression marks distinct populations within the B cell lineage:

• Constitutively expressed on marginal zone B cells

• Absent on follicular B cells

• Absent on germinal center B cells

• Present on plasma cells (both IgM+ and isotype-switched)

Comparative Expression Table:

Quantitative Analysis Approaches:

• Measure mean fluorescence intensity (MFI) rather than just percent positive cells

• Track temporal changes in expression levels during differentiation

• Perform cluster analysis to identify populations with similar marker expression patterns

• Use dimensionality reduction techniques (e.g., tSNE, UMAP) for visualization

What experimental controls are critical for validating CD9 function in knockout or knockdown studies?

When conducting CD9 knockout or knockdown studies, the following experimental controls are critical for valid interpretation:

Genetic Manipulation Controls:

• Validation of Knockout/Knockdown Efficiency:

  • Verify CD9 deletion at DNA level using PCR

  • Confirm absence of CD9 mRNA using RT-PCR or RNA-seq

  • Demonstrate protein absence using western blot and flow cytometry

  • Quantify knockdown efficiency when using siRNA or shRNA approaches

• Off-Target Effect Controls:

  • Use scrambled siRNA sequences for RNAi studies

  • Include wild-type littermates for genetic knockout models

  • Rescue experiments restoring CD9 expression to confirm phenotype specificity

Functional Validation Controls:

• Positive Controls:

  • Include known CD9-dependent processes (e.g., cell adhesion assays)

  • Use cell types with established CD9 functions (e.g., platelets, exosomes)

• Negative Controls:

  • Test CD9-independent functions to demonstrate specificity

  • Include CD19-deficient mice as a comparative model since CD19 affects B cell development

• Strain-Specific Controls:

  • Use multiple genetic backgrounds to account for strain-specific effects

  • Include CBA/CaN (xid) mice that show altered plasma cell CD9 expression

Phenotypic Analysis Guidelines:

• Analyze multiple B cell subsets including marginal zone, follicular, and plasma cells

• Examine both constitutive and inducible CD9 expression

• Assess both developmental and functional consequences of CD9 absence

• Compare in vitro and in vivo phenotypes to validate physiological relevance

How do changes in CD9 expression correlate with functional changes in B cells?

The correlation between CD9 expression and B cell functional changes provides important insights into the protein's biological significance:

Functional Correlation Analysis:

• CD9 expression on marginal zone B cells correlates with their specialized functions:

  • Enhanced responses to T-independent antigens

  • Rapid antibody production capabilities

  • Distinct adhesion properties

• CD9 induction during plasma cell differentiation coincides with:

  • Increased antibody secretion capacity

  • Altered migratory behavior

  • Changed adhesion properties

• CD9 expression on plasma cells correlates with their maturation state:

  • Present on both early IgM+ and later isotype-switched plasma cells

  • Maintained on long-lived plasma cells

  • Expressed alongside other plasma cell markers (Synd1, CD43, Ly6C)

Experimental Approaches to Assess Functional Correlation:

• Cell Sorting Based on CD9 Expression:

  • Compare functional capabilities of CD9+ vs. CD9- populations within the same lineage

  • Assess antibody secretion, proliferation, and survival

• Temporal Correlation:

  • Track CD9 expression alongside functional changes during differentiation

  • Determine whether CD9 expression precedes or follows functional changes

• Manipulation Studies:

  • Block CD9 function using antibodies and assess impact on B cell functions

  • Correlate CD9 expression levels with functional readouts using dose-response analysis

Research indicates that CD9 may function in cell-cell adhesion in pre-B cells and potentially participates in signal transduction through interactions with low molecular weight GTP binding proteins . The protein's expression pattern suggests specific roles in marginal zone B cell function and plasma cell differentiation.

What emerging technologies can advance our understanding of CD9 function in immune regulation?

Several cutting-edge technologies hold promise for deepening our understanding of CD9 function in immune regulation:

Single-Cell Technologies:

• Single-Cell RNA Sequencing (scRNA-seq):

  • Map CD9 expression across the entire immune repertoire at single-cell resolution

  • Identify previously unrecognized CD9+ populations

  • Correlate CD9 expression with global transcriptional programs

• CyTOF (Mass Cytometry):

  • Simultaneously analyze CD9 alongside dozens of other markers

  • Create high-dimensional phenotypic maps of CD9+ cells

  • Track rare subpopulations through development and activation

Advanced Imaging Approaches:

• Super-Resolution Microscopy:

  • Visualize CD9 distribution within tetraspanin-enriched microdomains

  • Track CD9 dynamics during immune synapse formation

  • Analyze co-localization with signaling partners at nanoscale resolution

• Intravital Imaging:

  • Monitor CD9+ cell behavior in living tissues

  • Track migration, interaction, and function of CD9+ cells in real-time

  • Assess the impact of CD9 blockade on cellular dynamics

Genetic Manipulation Technologies:

• CRISPR-Cas9 Gene Editing:

  • Generate precise mutations in CD9 functional domains

  • Create conditional knockout models for temporal control of CD9 expression

  • Introduce reporter tags to track CD9 expression without antibodies

• AAV-Mediated Gene Transfer:

  • Restore CD9 expression in specific cell types in knockout models

  • Express modified versions of CD9 to assess domain-specific functions

How might CD9's role in exosome biology inform therapeutic approaches?

CD9's established role as an exosome marker opens several avenues for therapeutic development:

Exosome-Based Therapeutic Applications:

• Engineered Exosomes for Targeted Delivery:

  • CD9 can serve as an anchor point for therapeutic cargo loading

  • CD9-enriched exosomes may have distinct targeting properties

  • Manipulating CD9 levels may alter exosome uptake by recipient cells

• Exosome-Based Biomarkers:

  • CD9+ exosomes from specific cellular sources may serve as disease biomarkers

  • Ratio of CD9 to other tetraspanins (CD63, CD81) on exosomes may indicate cellular origin

  • Changes in exosomal CD9 levels may reflect alterations in immune cell activation

Methodological Approaches for Exosome Research:

• Isolation and Characterization:

  • Anti-CD9 antibodies can be used for immunocapture of exosomes

  • CD9 quantification helps standardize exosome preparations

  • Multiple tetraspanin markers (CD9, CD63, CD81) provide comprehensive exosome characterization

• Functional Analysis:

  • Compare functions of CD9-high versus CD9-low exosome populations

  • Assess the impact of CD9 blockade on exosome uptake and function

  • Investigate CD9's role in protein sorting into multivesicular bodies (MVBs) and exosomes

Tetraspanins like CD9 are thought to play a role in the targeting of proteins to multivesicular bodies and exosomes, making them valuable targets for engineering exosome-based therapeutics . Understanding CD9's contribution to exosome biogenesis and function could lead to novel approaches for treating immune-mediated diseases.

What are the key unresolved questions regarding CD9 in B cell development and function?

Despite significant advances in our understanding of CD9 biology, several important questions remain unresolved:

Developmental Biology Questions:

• Lineage Determination:

  • Does CD9 expression influence cell fate decisions in B cell development?

  • What transcription factors regulate CD9 expression in different B cell subsets?

  • Why do marginal zone B cells constitutively express CD9 while follicular B cells do not?

• Functional Significance:

  • Does CD9 directly contribute to the specialized functions of marginal zone B cells?

  • What is the functional significance of CD9 induction during plasma cell differentiation?

  • How does CD9 interact with other tetraspanins in specialized membrane microdomains?

Methodological Approaches to Address These Questions:

• Lineage Tracing Studies:

  • Track the fate of CD9+ progenitors throughout B cell development

  • Use inducible reporter systems to visualize CD9 expression dynamics

  • Perform adoptive transfer experiments with sorted CD9+ versus CD9- populations

• Molecular Interaction Analysis:

  • Identify CD9 binding partners in different B cell subsets using proximity labeling

  • Map the interactome of CD9 during different stages of B cell differentiation

  • Investigate the impact of CD9 on membrane organization and signaling complex formation

• Functional Genomics:

  • Perform transcriptional profiling of sorted B cell populations based on CD9 expression

  • Use ATAC-seq to identify open chromatin regions associated with CD9 expression

  • Implement ChIP-seq to identify transcription factors regulating CD9 expression